Shire Licenses Genetic Disease Therapy to Amicus
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 90 (Table of Contents)
Published: 7 Dec-2007
DOI: 10.3833/pdr.v2007.i90.251 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Shire Human Genetic Therapies and Amicus Therapeutics entered into license agreement for Amicus’ products - Amigal™ (migalastat hydrochloride) for treating Fabry’s disease and Plicera™ (isofagomine tartrate) for treating Gaucher’s disease, both of which are in phase 2 clinical trials and AT2220 which is in phase 1 clinical trials for treating Pompe disease...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS